IPCA Laboratories · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Unichem's EBITDA margin declined due to loss of market share in high-margin US products, one-time provisions (EU penalty revaluation, Ireland closure), and weakness in Asia/Brazil. Management does not expect EBITDA growth in FY26.
Management noted that the UK market was 'very fiercely competitive' with excess inventory and prices falling below cost for some products, impacting IPCA's UK business.
Onyx (CDMO) reported a loss due to reduced project initiations; Pisgah (injectables) is still pre-commercialization. Management expects these to remain a drag for 1-2 years.
Domestic CV therapy growth slowed to ~8% due to reorganization (adding 400 MRs). Recovery is expected but near-term growth may be subdued.
